Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease

Xie, Fengjiao; Xiong, Qin; Yilin, Li; Yao, Chengjiao; Wu, Ruike; Wang, Qiuxiang; Luo, Lihong; Liu, Hongling; Yao, Chengjiao

doi:10.1155/2022/6275136

Cited by 7 publications

(3 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20,21 Owing to the incurable other hand, TCM has an important role in preventing and treating IBD that effectively alleviate symptoms, improve immunity, and curb progression of the disease. 23 TCM has unique advantages of having low adverse effects and stable efficacy in the overall treatment and maintenance phases of IBD. For example, the isolated rutaecarpine (RUT), a COX-2 inhibitor isolated from Evodia rutaecarpa, could improve dextran sodium sulfate (DSS)-induced IBD and inhibited oxidative stress.…”

Section: Keyword Analysismentioning

confidence: 99%

Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease

Wang,

Chen,

Yuan

2024

Allergol Immunopathol

View full text Add to dashboard Cite

Objective: This study conducts a bibliometric analysis of literature on the treatment of inflammatory bowel disease (IBD) with traditional Chinese medicine (TCM) to explore its research status, hotspots, and development trends, providing ideas and references for further research. Method: We screened literature for treating IBD with TCM from the Web of Science Core Collection (WOSCC), and used the VOSviewer software (1.6.18) to discover cooperation among countries, institutions, authors, and information on journals, keywords, etc. We use the CiteSpace software (6.2.R2) to analyze co-citation and burst discovery of references. Results: In all, 440 relevant literature papers were searched and screened from the WOSCC database. The results showed that the number of publications concerning treating IBD with TCM has shown a significant growth in the past decade. China is far ahead in terms of article output, occupying a dominant position. The institution with the most published articles is Nanjing University of Traditional Chinese Medicine. The authors who have published most of the articles are Dai Yancheng, Shi Rui, and Zhou Lian. The Journal of Ethnopharmacology published maximum articles in this field, while Gastroenterology was the most cited journal. Ungaro et al.’s article entitled “Ulcerative colitis” (https://doi.org/10.1016/S0140-6736(16)32126-2), published in The Lancet in 2017 was the most cited study. The high-frequency keywords mainly include ulcerative colitis, inflammation, NF-κB, expression, traditional Chinese medicine, gut microbiota, activation, mice, cells, etc. Conclusions: The research heat for treating IBD with TCM has risen over the past decade, with studies focusing on three main aspects: clinical studies of TCM, basic pharmacology, and animal experimental research. The research hotspot shifted from pathogenesis, clinical study of TCM, basic pharmacology, and complementary therapies to the study of network pharmacology and the mechanism of action of TCM related to gut microbiota. Network pharmacology and gut microbiota are at the frontiers of research and turning to be the future research trends to provide new insights and ideas for further research for treating IBD with TCM.

show abstract

Section: Keyword Analysismentioning

confidence: 99%

Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease

Wang,

Chen,

Yuan

2024

Allergol Immunopathol

View full text Add to dashboard Cite

show abstract

“…The components of medicine food homology (MFH) are complex and can treat intestinal diseases by exerting anti-inflammatory and antioxidant effects, as well as regulating the intestinal flora [ 315 ]. In addition, a growing body of research has demonstrated that TCM has great potential in treating intestinal diseases by regulating intestinal immunity and inflammation through the AHR pathway [ 316 ]. Eating MFH will have a beneficial effect on intestinal health.…”

Section: Dietary Habits Affect Intestinal Health Through Ahrmentioning

confidence: 99%

Modulating AHR function offers exciting therapeutic potential in gut immunity and inflammation

Chen

Wang

et al. 2023

Cell Biosci

View full text Add to dashboard Cite

Aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is a classical exogenous synthetic ligand of AHR that has significant immunotoxic effects. Activation of AHR has beneficial effects on intestinal immune responses, but inactivation or overactivation of AHR can lead to intestinal immune dysregulation and even intestinal diseases. Sustained potent activation of AHR by TCDD results in impairment of the intestinal epithelial barrier. However, currently, AHR research has been more focused on elucidating physiologic AHR function than on dioxin toxicity. The appropriate level of AHR activation plays a role in maintaining gut health and protecting against intestinal inflammation. Therefore, AHR offers a crucial target to modulate intestinal immunity and inflammation. Herein, we summarize our current understanding of the relationship between AHR and intestinal immunity, the ways in which AHR affects intestinal immunity and inflammation, the effects of AHR activity on intestinal immunity and inflammation, and the effect of dietary habits on intestinal health through AHR. Finally, we discuss the therapeutic role of AHR in maintaining gut homeostasis and relieving inflammation. Graphical Abstract

show abstract

“…At the same time, the body produces large amounts of cytokines, proteolytic enzymes, and free radicals, which eventually lead to inflammation and ulcers [1,2]. According to a study in the United States, IBD is listed as the fifth most expensive gastrointestinal disease, and its patients accumulate additional Molecules 2024, 29, 379 2 of 27 out-of-pocket costs of nearly $500 million per year in treatment [3]. The treatment of this disease is not ideal due to the lack of medicine with enough efficiency and efficacy, although recent studies have made significant progress in understanding the pathogenesis of IBD.…”

Section: Introductionmentioning

confidence: 99%

Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease

Yao,

Liu,

et al. 2024

Molecules

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic and recurrent intestinal inflammatory disease, mainly including Crohn’s disease (CD) and ulcerative colitis (UC). In recent years, the incidence and prevalence of IBD have been on the rise worldwide and have become a significant concern of health and a huge economic burden on patients. The occurrence and development of IBD involve a variety of pathogenic factors. The changes in short-chain fatty acids (SCFAs) are considered to be an important pathogenic mechanism of this disease. SCFAs are important metabolites in the intestinal microbial environment, which are closely involved in regulating immune, anti-tumor, and anti-inflammatory activities. Changes in metabolite levels can reflect the homeostasis of the intestinal microflora. Recent studies have shown that SCFAs provide energy for host cells and intestinal microflora, shape the intestinal environment, and regulate the immune system, thereby regulating intestinal physiology. SCFAs can effectively reduce the incidence of enteritis, cardiovascular disease, colon cancer, obesity, and diabetes, and also play an important role in maintaining the balance of energy metabolism (mainly glucose metabolism) and improving insulin tolerance. In recent years, many studies have shown that numerous decoctions and natural compounds of traditional Chinese medicine have shown promising therapeutic activities in multiple animal models of colitis and thus attracted increasing attention from scientists in the study of IBD treatment. Some of these traditional Chinese medicines or compounds can effectively alleviate colonic inflammation and clinical symptoms by regulating the generation of SCFAs. This study reviews the effects of various traditional Chinese medicines or bioactive substances on the production of SCFAs and their potential impacts on the severity of colonic inflammation. On this basis, we discussed the mechanism of SCFAs in regulating IBD-associated inflammation, as well as the related regulatory factors and signaling pathways. In addition, we provide our understanding of the limitations of current research and the prospects for future studies on the development of new IBD therapies by targeting SCFAs. This review may widen our understanding of the effect of traditional medicine from the view of SCFAs and their role in alleviating IBD animal models, thus contributing to the studies of IBD researchers.

show abstract

Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease

Cited by 7 publications

References 93 publications

Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease

Bibliometric analysis of traditional Chinese medicine in the treatment of inflammatory bowel disease

Modulating AHR function offers exciting therapeutic potential in gut immunity and inflammation

Short Chain Fatty Acids: Essential Weapons of Traditional Medicine in Treating Inflammatory Bowel Disease

Contact Info

Product

Resources

About